Feline Giardiasis

Feline giardiasis is a parasitic intestinal infection caused by the protozoan Giardia duodenalis (also known as Giardia intestinalis or Giardia lamblia), which colonizes the small intestine of cats and can lead to acute or chronic gastrointestinal disturbance [1]. The parasite exists in two morphological forms: the motile trophozoite that adheres to intestinal epithelium and the environmentally resistant cyst that is shed in feces and serves as the infective stage [3]. Giardiasis is particularly prevalent in young cats and in densely housed populations such as catteries, where conditions favor rapid transmission [4]. In cats, assemblage F is the most commonly identified genotype, although zoonotically relevant assemblages have also been detected, raising public health considerations [1].

Giardia duodenalis is a flagellated protozoan classified as a facultative pathogen, meaning infection does not invariably result in clinical disease [1]. The organism is organized into eight genotypic assemblages (A through H); in cats, assemblage F predominates, while assemblages A and B — which are zoonotically significant — may also be detected [1].

Life cycle and transmission: Cats become infected by ingesting environmentally resistant cysts, typically through fecal-oral contamination — consuming contaminated water, grooming fur soiled with infected feces, or direct contact with infected animals or fomites [3]. Overcrowding and high environmental humidity promote cyst survival and facilitate rapid transmission within group-housed populations such as catteries [4]. Cysts excyst in the small intestine, releasing trophozoites that multiply by binary fission and colonize the duodenum and jejunum.

Pathological mechanism: Trophozoites use a ventral adhesive disc to attach to the brush border epithelium of enterocytes. This attachment causes villous blunting, microvillous damage, and disruption of tight junctions, leading to a functional and, in severe cases, morphological compromise of the intestinal absorptive surface [3]. The result is maldigestion and malabsorption — particularly of fats and fat-soluble vitamins — which underlies the characteristic steatorrhea and weight loss. There may also be increased intestinal permeability, accelerated intestinal transit, and an osmotic component to diarrhea. Host immune status, infective dose, and concurrent infections (e.g., other enteropathogens) all influence whether clinical disease develops [1][4].

Diagnosis of feline giardiasis relies on the direct or indirect detection of the parasite's cyst or trophozoite stages in fecal specimens, as clinical signs alone are nonspecific [3].

Fecal examination:

• ·Zinc sulfate centrifugal flotation is the preferred concentration technique and is considered the gold standard for cyst detection; a modified zinc sulfate technique using centrifugation significantly increases sensitivity compared to simple flotation [5]. Multiple fecal samples (ideally three samples collected on alternate days) are recommended to compensate for the intermittent nature of cyst shedding [3].
• ·Direct fecal smear using saline allows visualization of motile trophozoites; this method is most productive with fresh, liquid stool and is less sensitive for subclinical infections [3].
• ·Fecal ELISA (enzyme-linked immunosorbent assay) and immunofluorescence assay (IFA): Antigen-based ELISA kits and IFA tests targeting Giardia surface antigens offer higher sensitivity than conventional microscopy and can detect antigen even when cyst numbers are low [1].
• ·Polymerase chain reaction (PCR): Molecular methods provide the highest sensitivity and specificity, and additionally allow assemblage typing to distinguish zoonotically relevant genotypes from feline-specific assemblage F [1].

Laboratory findings: Routine hematology and serum biochemistry are not diagnostic for giardiasis but may reveal secondary abnormalities in affected cats:

• ·HCT (hematocrit): May be mildly decreased (low-normal to mild anemia) in cats with chronic disease and poor nutritional status.
• ·ALB (albumin): May be low-normal or mildly decreased due to protein malabsorption in protracted infections.
• ·GLOB (globulins): May be mildly elevated as part of a nonspecific immune response.
• ·ALT: Generally within reference range; marked elevation would prompt investigation for concurrent hepatic disease.
• ·BUN/CREA: Usually normal; pre-renal azotemia could occur if severe dehydration accompanies profuse diarrhea.
• ·WBC: Typically within normal limits; eosinophilia is not a characteristic feature of intestinal protozoan infections in general.

These laboratory parameters are useful for assessing overall patient condition and ruling out concurrent disease rather than confirming giardiasis specifically.

Antiparasitic therapy:

• ·Metronidazole is the most widely used first-line treatment for feline giardiasis [3][5]. A commonly studied protocol is 22 mg/kg twice daily for 5 days, which has demonstrated efficacy in eliminating cyst shedding in infected cats [5]. Metronidazole is selected both for its antiprotozoal activity and its anti-inflammatory effects on the intestinal mucosa [6]. Adverse effects at therapeutic doses may include anorexia and, at higher doses, neurological signs; dosing should be carefully managed in cats.
• ·Fenbendazole (a benzimidazole anthelmintic) is used as an alternative or adjunct, typically at 50 mg/kg once daily for 5 days. It is often preferred in cats that do not tolerate metronidazole, and combination therapy (metronidazole + fenbendazole) may be considered in refractory cases [1].

Supportive care:

• ·Dietary management: A highly digestible, low-fat diet is recommended during treatment to reduce the malabsorptive burden and improve stool consistency [4].
• ·Fluid therapy: Cats with significant dehydration secondary to profuse diarrhea and/or vomiting may require oral or parenteral fluid support.
• ·Probiotics: May be considered as adjunctive therapy to support restoration of intestinal microbiota, though evidence-based recommendations specific to cats remain limited.

Environmental decontamination: Because reinfection from the environment is a major obstacle to successful elimination, concurrent environmental cleaning is essential. Quaternary ammonium compounds or dilute bleach solutions are effective at inactivating cysts on surfaces; steam cleaning is also recommended for bedding and housing. All in-contact cats in a multi-cat household should be evaluated and treated simultaneously to prevent reinfection [4].

The prognosis for feline giardiasis is generally excellent for otherwise healthy cats receiving appropriate treatment. The condition is not considered a life-threatening disease in immunocompetent individuals, and mortality directly attributable to Giardia infection is not reported in the peer-reviewed literature cited here [1][3][4][5].

Most cats respond favorably to a standard course of metronidazole or fenbendazole, with resolution of clinical signs and cessation of cyst shedding within days to weeks of completing therapy [5]. However, reinfection is common — particularly in multi-cat environments or catteries — if concurrent environmental decontamination is not undertaken, which can give the clinical appearance of treatment failure [4].

Cats with chronic infections may experience prolonged malnutrition and weight loss that can compromise overall condition, and these individuals require more intensive nutritional support alongside antiparasitic therapy. Young kittens, geriatric cats, and immunocompromised individuals (e.g., those coinfected with FeLV or FIV) face a greater risk of severe or persistent disease, and the prognosis in these subpopulations should be guarded until clinical response is confirmed.

Data on formal long-term survival statistics for feline giardiasis are not reported in the references cited above, consistent with its characterization as a self-limiting to treatable disease with low mortality in the general feline population.

Environmental management:

• ·Minimizing overcrowding in catteries, shelters, and multi-cat households is a primary preventive measure, as high stocking density directly promotes fecal-oral transmission [4].
• ·Maintaining low environmental humidity and implementing rigorous hygiene protocols — including prompt removal of feces, regular disinfection of litter boxes, food and water bowls, and housing surfaces — substantially reduces cyst survival in the environment [4].
• ·Fresh, clean water should be provided at all times; standing or shared water sources are a potential route of cyst ingestion [3].
• ·Cats should be prevented from grooming each other excessively in infected households during and after treatment; bathing cats to remove cysts from the perineal area and coat can reduce autoinfection and environmental contamination [1].

Vaccination:

• ·A Giardia vaccine was developed and made commercially available in the United States, intended to reduce clinical signs of giardiasis and decrease cyst shedding in dogs and cats [2]. The vaccine was developed based on knowledge of Giardia antigenicity and immunology and demonstrated efficacy in immunoprophylactic and immunotherapeutic applications in experimental and field studies [2]. However, availability and routine use of this vaccine have varied by region and time period, and clinicians should verify current availability and regulatory status in their jurisdiction.

Testing and quarantine:

• ·New cats introduced to a household or cattery should be screened by fecal examination prior to commingling with resident animals.
• ·Infected animals should be isolated and fully treated — with confirmed clearance of cyst shedding — before reintroduction to group housing [4].

Zoonotic considerations:

• ·Although assemblage F (the predominant cat-associated genotype) is not considered a major zoonotic risk, zoonotically relevant assemblages A and B have been detected in cats [1]. Immunocompromised owners should exercise particular caution with hand hygiene when handling cats with known or suspected giardiasis.

**